Michael Evan Lidsky

Conference J Natl Cancer Inst · July 1, 2026 BACKGROUND: Small bowel adenocarcinoma (SBA) is a rare malignancy with poor prognosis. Its clinical and pathologic characteristics are sparse, and few studies have examined its genetic features within the continuum of the gastrointestinal tract. METHODS: P ... Full text Link to item Cite

Abstract C025: Effect of Chemotherapy on Spatial Relationships in the Colorectal Cancer Immune Microenvironment

Conference Cancer Immunology Research · February 18, 2026 AbstractMicrosatellite stable (MSS) stage IV colorectal cancer (CRC) is treated with chemotherapy (CT) and targeted therapy, but resistance is common, with only a 13% 5-year overall survival, and more eff ... Full text Cite

Social Vulnerability as a Neighborhood-Level Determinant of Pancreatic Cancer Survivorship: A National Analysis of Veterans Affairs Patients.

Conference Ann Surg Oncol · February 2026 BACKGROUND: Veterans Affairs (VA) patients participate within the largest USA equal-access healthcare system, though still experience cancer mortality disparities by social determinants. The Social Vulnerability Index (SVI)-measuring community poverty, min ... Full text Link to item Cite

ctDNA as a novel biomarker of treatment efficacy in patients with unresectable colorectal liver metastases treated with hepatic arterial infusion

Conference ANNALS OF SURGICAL ONCOLOGY · March 2025 Link to item Cite

Genome-Derived Classification Signature of Pancreatic Acinar Cell Carcinoma Reveals Association with KRAS Wildtype Pancreatic Ductal Adenocarcinoma

Conference ANNALS OF SURGICAL ONCOLOGY · March 2025 Link to item Cite

Perioperative and Oncologic Outcomes of Hepatic Arterial Infusion (HAI) Pump Chemotherapy for Patients with Unresectable Colorectal Liver Metastases at an Expanding HAI Program.

Conference Ann Surg Oncol · February 2025 BACKGROUND: Hepatic arterial infusion (HAI) is an established treatment for patients with unresectable colorectal liver metastases (uCRLM). Until recently, HAI was only performed at a limited number of centers. We previously reported early outcomes suggest ... Full text Link to item Cite

Abstract B052: Single-cell and spatial analysis of the immune landscape unveils a subset of potentially tumor-reactive T cells in patients with localized PDAC

Conference Cancer Research · September 15, 2024 AbstractEven in its localized stages, pancreatic ductal adenocarcinoma (PDAC) is virtually incurable, characterized by early dissemination and disease recurrence. The liver is the most common site of metasta ... Full text Cite

Contemporary Trends, Management, and Outcomes for Patients with Diffuse Type Gastric Cancer

Conference ANNALS OF SURGICAL ONCOLOGY · March 2024 Link to item Cite

Unsupervised clustering using multiple correspondence analysis reveals clinically-relevant demographic variables across multiple gastrointestinal cancers

Conference ANNALS OF SURGICAL ONCOLOGY · March 2024 Link to item Cite

A novel classification of small bowel adenocarcinoma based on a hidden genome classifier: A multi-institutional study.

Conference Journal of Clinical Oncology · January 20, 2024 724Background: Small bowel adenocarcinoma (SBA) is a rare malignancy with poor prognosis. Data describing the clinical and pathologic characteristics of this disease are sparse, and few studies examine the genetic footprint of SBAs within the continuum of ... Full text Cite

Abstract B022: A platform to characterize hepatic immunity reveals variation in hepatic infiltration of tumor expanded T cells in “localized” PDAC

Conference Cancer Research · January 16, 2024 AbstractEven in its earliest stages, pancreatic ductal adenocarcinoma (PDAC) is an essentially incurable disease due to the presence of disseminated, yet radiographically occult cancer cells in the setting o ... Full text Cite